7 completed. 7 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis CNM-Au8 - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Clene Nanomedicine | 55 | 2020-10-22 | 2023-12-08 |
| Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis Tolebrutinib - Relapsing Multiple Sclerosis | Phase 2 | Completed | Sanofi | 125 | 2019-09-23 | 2025-10-23 |
| Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI) - Relapsing Multiple Sclerosis | Phase 2 | Completed | Sanofi | 130 | 2019-03-29 | 2025-09-17 |
| Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab Ofatumumab, Matching placebo of ofatumumab - Relapsing Multiple Sclerosis | Phase 2 | Completed | Novartis Pharmaceuticals | 64 | 2018-03-15 | 2022-04-29 |
| Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients Ozanimod, Placebo - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Celgene | 258 | 2012-09-18 | 2021-02-11 |
| Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study Trichuris suis ova - Relapsing Multiple Sclerosis | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 10 | 2010-05-01 | 2011-11-10 |
| CDP323 Biomarker Study CDP323, Placebo - Relapsing Multiple Sclerosis | Phase 1 / Phase 2 | Completed | UCB Pharma | 71 | 2008-07-01 | 2011-09-12 |
Multiple Sclerosis (2) · Demyelinating Diseases (1) · Optic Nerve Diseases (1) · Optic Neuritis (1)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Immune System Diseases (2) · Nervous System Diseases (2) · Cranial Nerve Diseases (1) · Demyelinating Diseases (1) · Eye Diseases (1)
CDP323 (1) · ofatumumab (1) · ozanimod (1)
Sanofi (2) · Celgene (1) · Clene Nanomedicine (1) · Copenhagen University Hospital, Rigshospitalet (1) · Novartis Pharmaceuticals (1) · UCB Pharma (1)
Russia (4) · Spain (3) · Ukraine (3) · United States (3) · Canada (2) · Czechia (2) · Estonia (2) · France (2) · Netherlands (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Denmark (1) · Georgia (1) · Greece (1)
PMID 23472197, PMID 25698173, PMID 26879276, PMID 30043658, PMID 34418400
2018 (2)